Skip to content
Search

Latest Stories

Sector leaders urge Health Select Committee to hold government to account on pharmacy funding and workforce challenges

Pharmacy bodies have urged the Health Select Committee to hold the government to account on pharmacy funding and workforce challenges.

In a show of unity, leaders from the sector came together to write a joint letter to the chair of the committee and former health secretary Jeremy Hunt and bring to his attention how financial pressures worsened by nearly a decade of a real-term decrease in funding have made the sector virtually untenable.


The Pharmaceutical Services Negotiating Committee (PSNC)'s recently published ‘Pharmacy Pressures Survey' confirms how this has had an impact on pharmacy contractors, their teams as well as patients.

The survey found that 91 per cent of pharmacies are experiencing staff shortages. At the same time, demand for community pharmacists has risen – nine in ten pharmacy teams reported a significant increase in phone calls from patients about prescriptions, and 86 per cent reported a rise in requests for healthcare advice.

The letter to Jeremy Hunt is signed on behalf of the four chief executives of the PSNC, the Association of Independent Multiple Pharmacies (AIMp), the Company Chemists’ Association (CCA) and the National Pharmacy Association (NPA).

Dr Leyla Hannbeck, AIMp chief executive, said: “Over the past few years pharmacy teams have demonstrated very clearly their rightful place as the front door to the NHS. Their enthusiasm and hard work have been praised by the public and the politicians alike. We are willing and ready to step up and further be a solution to the current challenges within the NHS. But our sector is exhausted and starved of funding since many years. It needs prompt support and investment. The positive words need to turn into action.”

Malcolm Harrison, chief executive of the CCA, said: “Businesses of all sizes are struggling after funding cuts, which date from 2016, and worsening workforce challenges and it’s imperative policymakers recognize and take action accordingly. Pharmacies want to play their part in alleviating the NHS backlog but are hamstrung by the current arrangements. The sector needs a funding settlement that truly reflects the value it provides to patients, the public and the NHS.”

Mark Lyonette, chief executive of NPA said: “Community pharmacy is a can-do sector that wants to deliver even more for patients and the NHS, but we need enough people to power this forward-looking agenda. Right now there is a shortage of pharmacists, other key staff and funds to invest in training. We want to work with government and the NHS on solutions, and a realistic level of overall funding has to be part of that.”

Janet Morrison OBE, chief executive, PSNC, said: "Community pharmacies are facing an unrelenting combination of financial and operational pressures, with workforce challenges high on the list of many contractors’ urgent problems. As we have stressed to MPs, the sector needs urgent investment and support to address these challenges, and to avoid patient services being detrimentally impacted.

"The last few years have shown just how important pharmacies are to the public and government must work with us to address workforce and other challenges so that we can avoid these critical healthcare locations being forced to close, whether temporarily or permanently."

More For You

13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less
 Government launches call for evidence on England’s first ever men’s health strategy

Wes Streeting

Pic credit: Getty images

Call for Evidence: Streeting urges public to help shape men’s health strategy

The government is urging men of all ages to come forward and contribute to the development of England’s first-ever men’s health strategy, a key initiative under its Plan for Change.

On Thursday (24), the Department of Health and Social Care (DHSC) launched a 12-week call for evidence, seeking insights from the public, health and social care professionals, academics and employers on ways to prevent and tackle the biggest issues facing men.

Keep ReadingShow less
Slamannan Village Pharmacy sold after 31 years

Slamannan Village Pharmacy

Slamannan Village Pharmacy sold after 31 years

A pharmacy in a small village in Scotland that has served its community for 31 years, has been bought by a group that operates 43 pharmacies across Scotland.

Slamannan Village Pharmacy is heavily relied on by locals sourcing their prescriptions from the village’s sole GP surgery.

Keep ReadingShow less
Kinnock highlights employers’ role in making community pharmacy jobs attractive

The new funding uplift our commitment to rebuilding the sector: Kinnock

Kinnock: ‘Employers have a key role in making community pharmacy jobs attractive’

Health minister Stephen Kinnock has emphasised that employers have a crucial role to play in retaining staff and making careers in community pharmacy more attractive.

His comments came in response to a written question from Victoria Collins MP, the Liberal Democrat spokesperson for science and technology, who asked what steps the Department of Health and Social Care is taking to address staff shortages and prevent the closure of local pharmacies.

Keep ReadingShow less
MHRA approves Pfizer Hympavzi (marstacimab) for haemophilia treatment

Marstacimab is currently being assessed by NICE and the Scottish Medicines Consortium for use on the NHS

gettyimages

Marstacimab approved for haemophilia treatment, Pfizer aims for NHS availability

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Hympavzi(marstacimab) to prevent or reduce bleeding in patients aged 12 years and older, weighing at least 35kg, who have severe haemophilia A or B.

Developed by Pfizer scientists, this groundbreaking treatment is the first of its kind to target a protein involved in the blood clotting process.

Keep ReadingShow less